Keywords: janssen-cilag, gains, uk, ok, exprex, cancer, patients

Janssen-Cilag gains UK OK for Exprex in cancer patients

Article | 29 March 2000

Print This

Janssen-Cilag says it has received clearance from the UK's MedicinesControl Agency to market Eprex (epoetin alfa) for the treatment of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in